| 453- | CUR, | Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 452- | CUR, | Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells |
| - | vitro+vivo, | HNSCC, | SCC9 | - | vitro+vivo, | HNSCC, | FaDu | - | vitro+vivo, | HNSCC, | HaCaT |
| 451- | CUR, | The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer |
| - | vitro+vivo, | HNSCC, | SCC15 | - | vitro+vivo, | HNSCC, | SNU1076 | - | vitro+vivo, | HNSCC, | SNU1041 |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| 449- | CUR, | Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a |
| - | vitro+vivo, | CRC, | SW480 |
| 448- | CUR, | Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation |
| - | in-vitro, | CRC, | HT-29 |
| 447- | CUR, | OXA, | Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway |
| - | vitro+vivo, | CRC, | HCT116 |
| 445- | CUR, | Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 444- | CUR, | Cisplatin, | LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells |
| - | vitro+vivo, | CRC, | HCT8 |
| 443- | CUR, | Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | SW480 |
| 442- | CUR, | 5-FU, | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress |
| - | in-vitro, | CRC, | HCT116 |
| 441- | CUR, | Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p |
| - | in-vitro, | CRC, | HCT116 |
| 440- | CUR, | Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HT-29 |
| 439- | CUR, | Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway |
| - | in-vitro, | CRC, | LGR5 |
| 438- | CUR, | Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats |
| - | vitro+vivo, | CRC, | CC531 |
| 135- | CUR, | Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 154- | CUR, | Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts |
| - | vitro+vivo, | Pca, | PC3 |
| 136- | CUR, | docx, | Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 140- | CUR, | Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling |
| - | in-vitro, | Pca, | PC3 |
| 141- | CUR, | Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer |
| - | in-vivo, | Pca, | PC3 |
| 142- | CUR, | Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts |
| - | in-vivo, | Pca, | LNCaP |
| 143- | CUR, | Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | PC, | DU145 | - | in-vitro, | PC, | LNCaP |
| 161- | CUR, | MeSA, | Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Pca, | DU145 |
| 146- | CUR, | EGCG, | Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 155- | CUR, | Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 151- | CUR, | Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | LNCaP |
| 152- | CUR, | Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 153- | CUR, | Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo |
| - | in-vivo, | Pca, | C4-2B |
| 126- | CUR, | Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 117- | CUR, | Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells |
| - | in-vivo, | Pca, | RM-1 | - | in-vivo, | Pca, | DU145 |
| 118- | CUR, | Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 120- | CUR, | A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation |
| - | Human, | Pca, | NA |
| 121- | CUR, | Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study |
| - | in-vivo, | Pca, | NA |
| 122- | CUR, | isoFl, | Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen |
| - | Human, | Pca, | LNCaP |
| 123- | CUR, | Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells |
| - | in-vitro, | Colon, | LoVo | - | in-vitro, | Colon, | COLO205 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 124- | CUR, | Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 125- | CUR, | Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway |
| - | in-vitro, | adrenal, | H295R |
| 134- | CUR, | RES, | MLT, | SIL, | Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 127- | CUR, | The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis |
| - | in-vitro, | Pca, | DU145 |
| 128- | CUR, | RES, | Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer |
| - | in-vivo, | Pca, | NA |
| 129- | CUR, | Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation |
| - | vitro+vivo, | Pca, | LNCaP |
| 130- | CUR, | Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 131- | CUR, | Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer |
| - | vitro+vivo, | Pca, | LNCaP | - | vitro+vivo, | Pca, | 22Rv1 |
| 132- | CUR, | Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 133- | CUR, | Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 158- | CUR, | Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 157- | CUR, | Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| - | Review, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid